At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
Enoxaparin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Assess Safety and Tolerability of Single Oral Doses of BMS-986177 in Patients With ESRD Treated With Chronic Hemodialysis
In Brief
A Phase 2 clinical trial evaluating Enoxaparin, unfractionated heparin (UFH), and 1 other intervention for Antithrombotic. Completed, enrolled 32 participants across 3 sites.
Detailed Summary
To investigate safety of Single Doses of BMS-986177 in Patients with End Stage Renal Disease treated with hemodialysis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAntithrombotic
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartMay 2017
Primary CompletionOct 2017
TodayJul 2026
First PostedDec 22, 2016
Enrollment StartMay 23, 2017
Primary CompletionOct 23, 2017
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 9.5 years ago
Interventions
Enoxaparindrug
Specified dose of Enoxaparin on specified days
unfractionated heparin (UFH)drug
Specified dose of UFH on specified days
BMS-986177drug
Specified dose of BMS-986177 on specified day